Cannabis and Heart Attacks: What a New Comprehensive Review of Recreational Drug-Associated ACS Actually Shows
| Audience | Cannabis-medicine clinicians, primary care and cardiology providers evaluating chest pain in cannabis users, and patients who use cannabis and want to understand cardiovascular risk |
| Primary Topic | A 2026 narrative review synthesizing the mechanisms, epidemiology, diagnosis, and management of acute coronary syndrome associated with recreational drug use, with a dedicated focus on what is specifically known about cannabis |
| Source | Read the full source |
Cannabis and Heart Attacks: What a New Comprehensive Review of Recreational Drug-Associated ACS Actually Shows
A newly published narrative review in Medicina synthesizes mechanistic, epidemiologic, and management evidence linking recreational drug use, including cannabis, cocaine, amphetamines, MDMA, opioids, and LSD, to acute coronary syndrome. Cannabis-specific findings cited in the review include a proposed nearly fivefold increase in myocardial infarction risk in the first hour after use, mechanistic pathways involving sympathetic activation and coronary vasospasm, and toxicology data showing cannabis as the most frequently detected drug among intensive cardiac care patients in one cohort. The review is a narrative synthesis of existing literature rather than a new controlled study, and its authors are explicit that much of the cannabis-specific mechanistic evidence remains indirect and requires further validation in humans.
| Study Type | Narrative literature review (not a systematic review or meta-analysis; evidence synthesized narratively due to heterogeneity across substances and study designs) |
| Search Strategy | PubMed/MEDLINE and Scopus, searched for literature published up to June 2026 |
| Substances Covered | Cannabis and synthetic cannabinoids, cocaine, amphetamines/methamphetamine, MDMA, opioids, LSD, and anabolic-androgenic steroids |
| Key Cannabis Finding | The review cites evidence that cannabis use is associated with a nearly fivefold increase in myocardial infarction risk within the first hour after use, notable even in young, otherwise healthy individuals with chest pain |
| Cannabis Detection Rate | In a multicenter intensive cardiac care unit study (ADDICT-ICCU) cited in the review, cannabis was the most frequently detected recreational drug (9.1% of patients), ahead of opioids (2.1%), cocaine (1.7%), and amphetamines (0.7%) |
| Cannabis in MI Registries | The YOUNG-MI registry, cited in the review, documented marijuana use in 6.0% of patients under 50 with type 1 MI, cocaine use in 4.7%, and both in 1.7% |
| Proposed Cannabis Mechanisms | THC-driven norepinephrine release and sympathetic activation, coronary vasospasm, carboxyhemoglobin elevation from smoking, oxidative stress and endothelial dysfunction, and possible THC-related platelet activation and procoagulant effects |
| Overall Drug-Associated ACS Finding | Recreational drug use of any kind was detected in 11% of ADDICT-ICCU patients and was independently associated with higher in-hospital major adverse cardiovascular events (adjusted OR 8.84, 95% CI 4.68-16.7; p < 0.001) |
| Journal / Publication | Medicina (Kaunas, Lithuania), published online July 30, 2026 |
| PMID / DOI | 42654374 / 10.3390/medicina62081477 |
The review describes several biologically plausible pathways by which THC, the primary psychoactive compound in cannabis, could trigger myocardial ischemia. THC acts as a mixed agonist at CB1 and CB2 cannabinoid receptors; CB1 receptors are present in the heart, adrenal glands, and adipose tissue, and THC-induced norepinephrine release can cause tachycardia, elevated blood pressure, and reduced left ventricular ejection fraction, increasing the heart’s oxygen demand in a dose-dependent way. At the same time, cannabis smoking may raise carboxyhemoglobin levels and provoke coronary vasospasm, reducing the oxygen supply the heart receives, a combination the authors describe as a supply-demand mismatch.
The review also cites case reports linking cannabis to transient myocardial ischemia from microvascular or epicardial coronary spasm, and notes that synthetic cannabinoids, which have longer half-lives and greater potency than THC, may produce more pronounced vasoconstriction. On clotting, the evidence is more mixed: platelet-function findings for THC remain conflicting across studies, though the authors point to research showing THC can prolong tissue factor expression in activated monocytes and increase platelet activation markers, findings they suggest may help explain case reports of thrombotic coronary occlusion in young cannabis users without underlying atherosclerosis. The authors note that much of this in vitro evidence used concentrations that may not reflect what circulates in humans after typical use.
In the ADDICT-ICCU study cited in the review, cannabis was the most frequently detected recreational drug on toxicology screening among intensive cardiac care unit patients, found in 9.1% of patients, more common than opioids (2.1%), cocaine (1.7%), or amphetamines (0.7%). Overall, recreational drug use of any kind was detected in 11% of ICCU patients in that study and was independently associated with a substantially higher risk of in-hospital major adverse cardiovascular events (adjusted odds ratio 8.84, 95% CI 4.68 to 16.7).
The review also cites the Partners YOUNG-MI registry, a retrospective analysis of patients under 50 with type 1 myocardial infarction, in which marijuana use was documented in 6.0% of patients, cocaine use in 4.7%, and both in 1.7%. Separately, the authors note that cannabis use has been associated with an increase in MI risk of nearly fivefold within the first hour after use, an effect window similar in kind, though smaller in magnitude, to the roughly 24-fold first-hour MI risk increase the same review reports for cocaine.
Compared with cocaine, which remains the best-studied recreational drug in this literature, the review positions cannabis as a less intensively studied but independently relevant trigger. Cocaine’s mechanisms, alpha-adrenergic vasoconstriction, elevated endothelin-1, and strong prothrombotic effects, are described in more mechanistic and quantitative detail than cannabis’s, which the authors attribute partly to cocaine’s longer research history in cardiology and partly to genuinely less mechanistic data existing for cannabis.
The review also flags that co-use matters: it cites evidence that combining cocaine and cannabis appears to increase cardiovascular risk beyond either drug alone, and that polysubstance detection generally, present in 28% of patients with a positive drug screen in the ADDICT-ICCU cohort, carried a higher odds of in-hospital major adverse events (OR 12.7) than single-drug detection (OR 8.84). For CED patients who use cannabis alongside other substances, including alcohol or stimulants, this is a relevant caution the review makes explicit rather than implied.
On toxicology testing, the review notes a practical limitation specific to cannabis: cannabinoids can remain detectable in urine for considerably longer than cocaine metabolites, particularly after frequent or chronic use. A positive cannabis screen in a patient presenting with chest pain confirms past exposure but does not by itself establish that cannabis was used recently enough to have triggered the acute event, a distinction the authors emphasize should temper how a positive result is interpreted clinically.
On treatment, the review’s discussion of beta-blockers, an area of real controversy for cocaine-associated ACS, does not extend the same blanket caution to cannabis. Instead, the authors state that in cannabis-associated ACS, beta-blocker therapy should be individualized according to hemodynamic status, left ventricular function, conduction abnormalities, and the underlying mechanism of ischemia, rather than withheld or given by default. Otherwise, the review recommends that drug-associated ACS, including cannabis-associated presentations, be managed according to standard ACS protocols, with drug-specific adjustments layered on top rather than substituted in.
The review situates cannabis-associated ACS within a larger, growing public health picture: the authors cite estimates that more than 53 million people worldwide had a drug use disorder in 2021, with a continuing projected rise, alongside a broader estimate of 316 million people reporting recreational drug use of any kind in the past year. Cannabis is among the most commonly used substances in that population, which the authors argue is part of why cardiologists increasingly need to treat recreational drug use as a routine part of ACS history-taking rather than an incidental social detail.
This review adds a mechanistic and epidemiologic synthesis to a theme CED has tracked through individual signals, including an earlier case report describing extensive coronary thrombosis in a young chronic cannabis user with a proposed cannabinoid-receptor mechanism, and a separate study on stroke risk associated with cannabis, cocaine, and amphetamine use. Read together, those individual signals and this broader review point in a consistent direction without any single source proving causation on its own.
What stands out to me most in this review is not any single finding but the pattern across sources: cannabis keeps showing up as a detectable, often undisclosed factor in patients presenting with acute coronary syndrome, and it is turning up more often on toxicology screens than cocaine or opioids in at least one sizable cardiac care cohort. That does not mean cannabis is as cardiotoxic as cocaine, the review is careful not to claim that, but it does mean I should be asking about cannabis use as routinely as I ask about tobacco when a patient describes chest pain, palpitations, or an unexplained cardiac event.
I also want to be honest about where this evidence is thin. The proposed mechanisms for cannabis, sympathetic activation, vasospasm, platelet effects, are plausible and consistent with what we know about THC pharmacology, but the authors themselves say the human evidence needs more validation. I read this review as a solid reason to take cannabis-associated chest pain seriously and to counsel patients honestly about a real, if still incompletely characterized, cardiovascular signal, not as proof that cannabis use causes heart attacks in a way that has been definitively established.
- Cannabis and Cardiovascular Risk: A Critical Review: a closer look at why a large meta-analysis linking cannabis to cardiovascular risk falls short of proving causation.
- Inhaled Cannabis and Daily Ectopic Heartbeats: a preliminary clinical trial finding that inhaled cannabis may reduce the frequency of ectopic heartbeats in regular users.
- Cannabis Use Disorder and Heart Attack Risk: a critical analysis of a study linking cannabis use disorder to heart attack risk in hospitalized cirrhosis patients.
- CBD Gummies and Cardiovascular Health: What the Evidence Shows: a review of current evidence on CBD gummies and heart health, including possible blood pressure benefits and remaining safety gaps.
- Unexpected Findings Add New Insight on Cannabis and Heart Health: coverage of a UC San Francisco study finding roughly 9% fewer premature heartbeats on days participants used cannabis compared with abstinence days.
- Cannabis and Vascular Function: A JAMA Cardiology Study: a critical analysis of a JAMA Cardiology study reporting reduced vascular function in cannabis users, and the limits on what it can prove.
How to Read a Narrative Review Without Overstating Its Certainty
A narrative review like this one is different from a systematic review or meta-analysis. It does not pool data into a single effect size, and it does not apply a formal, pre-registered protocol for which studies to include or how to weigh them. That does not make it useless, the authors’ clinical synthesis has real value, but it changes how a reader should treat its claims.
This review is especially useful for connecting scattered cannabis-specific findings, case reports, registry subgroup data, in vitro mechanism studies, into one coherent picture. The risk is in reading that coherent picture as if it carried the same certainty as a large randomized trial or meta-analysis, when it does not.
Four distinctions worth keeping straight
Narrative synthesis is not pooled evidence
No effect size in this review, including the nearly fivefold first-hour MI risk figure attributed to cannabis, is a pooled estimate from a meta-analysis. Each number traces back to a specific cited study, and its precision and generalizability should be judged against that individual source, not treated as a review-wide certainty rating.
Registry data shows association, not proof of causation
The ADDICT-ICCU and YOUNG-MI findings are observational. They show that cannabis use correlates with certain cardiac presentations and outcomes; they do not, by themselves, prove that cannabis caused a given patient’s event rather than coinciding with other risk factors.
Mechanism plausibility is not human confirmation
The proposed cannabis mechanisms, sympathetic activation, vasospasm, platelet effects, are pharmacologically plausible and partly supported by case reports and in vitro work. The review’s own authors state this mechanistic picture still requires further validation in human studies, a caveat worth repeating to patients rather than treating the mechanism as settled fact.
A detectable drug is not automatically the cause of the event
Because cannabinoids can remain detectable in urine long after use, a positive toxicology screen in a patient with ACS confirms exposure, not necessarily a temporal or causal link to that specific cardiac event. The review makes this distinction explicit rather than leaving it implied.
Cannabis and Cardiac Risk, Seen From Eight Angles
Eight perspectives on what a new comprehensive review of recreational drug-associated acute coronary syndrome means specifically for cannabis use.
A Real Signal Worth a Conversation, Not a Reason to Panic
If you use cannabis, this review is a reasonable prompt to mention that use to your clinician, especially if you have ever had chest pain, a racing heart, or other cardiac symptoms during or shortly after use. The review cites evidence that cannabis has been linked to a higher short-term risk of myocardial infarction, particularly in the first hour after use.
That said, this is a narrative review of existing studies, not a new trial proving that cannabis reliably causes heart attacks. Most people who use cannabis do not have a cardiac event. The honest takeaway is that cannabis is a real, if incompletely understood, cardiovascular variable worth discussing openly rather than hiding from a clinician.
Add Cannabis to Chest Pain and Toxicology Workups Explicitly
This review supports treating cannabis use as a specific, nameable item in the substance-use history for any patient presenting with unexplained chest pain, arrhythmia, or an unexplained STEMI or NSTEMI, particularly in younger patients with few traditional risk factors. The finding that cannabis outpaced cocaine, opioids, and amphetamines on toxicology screening in one ICCU cohort is a useful reminder not to anchor on stimulants alone.
Because cannabinoids stay detectable longer than many other drugs, a positive screen should prompt a careful history rather than an assumption of acute causation. Individualize beta-blocker use in cannabis-associated ACS based on hemodynamic status and left ventricular function, as the review recommends, rather than applying cocaine-specific caution by default.
A Narrative Review, Not a Meta-Analysis
This is a narrative review, meaning the authors selected and synthesized literature without a pre-registered systematic protocol or formal risk-of-bias scoring. The cannabis-specific mechanistic claims lean heavily on case reports and in vitro work, evidence tiers that are useful for generating hypotheses but not for confirming them.
The authors’ own knowledge-gaps section states plainly that the contribution of CB1 activation, oxidative stress, and inflammation to cannabis-induced myocardial ischemia requires further human validation. That is an honest admission worth taking at face value rather than glossing over in favor of the more dramatic mechanism narrative.
What the Full Text Adds Beyond the Abstract
Reading the full text rather than the abstract surfaces detail the abstract compresses: the specific ADDICT-ICCU detection rates by substance, the YOUNG-MI registry’s exact prevalence figures, and the authors’ explicit statement that marijuana’s relationship to post-MI mortality remains controversial given limitations in the underlying cohort study.
The full text also shows that the review’s cannabis-specific treatment guidance, individualizing beta-blocker use based on hemodynamics and left ventricular function, appears in the knowledge-gaps discussion rather than as a headline recommendation, useful context for how much weight to give it in practice.
Cocaine Has a Longer Research History Than Cannabis in This Field
The review itself notes that cocaine remains the best-studied recreational drug in cardiology, with decades of mechanistic and clinical research behind it, including a well-characterized case-crossover finding of a roughly 24-fold increase in MI risk in the first hour after use. Cannabis research in this specific area is comparatively newer and thinner.
That imbalance is visible in the review’s own structure: the cocaine sections cite more quantitative, registry-level detail, while cannabis sections more often rely on case reports and smaller mechanistic studies, a gap the authors implicitly acknowledge rather than obscure.
What This Means for Counseling Cannabis Patients Today
In practice, this review supports asking every patient who reports chest pain, palpitations, or cardiac symptoms about recent cannabis use, and documenting that history explicitly rather than assuming it is irrelevant if the patient does not smoke tobacco or use other drugs.
It also supports a measured conversation: acknowledging a real, biologically plausible cardiovascular signal associated with cannabis, without telling patients that cannabis use is equivalent to cocaine use in cardiac risk, a comparison this review’s own data does not support.
What Would Strengthen the Cannabis-Specific Evidence
The review’s authors call for larger, prospective studies with standardized toxicology protocols and substance-specific risk assessment. For cannabis specifically, that would mean moving beyond case reports and registry subgroup analyses toward dedicated, adequately powered human studies of the proposed CB1, oxidative-stress, and platelet mechanisms.
The authors also flag that current ACS risk-stratification scores do not include recreational drug use at all, cannabis or otherwise, suggesting a concrete, testable next step: incorporating substance-use history, including cannabis, into risk models for young patients presenting with chest pain.
Toxicology Screening and Disclosure in a Changing Legal Landscape
As cannabis access has expanded in many jurisdictions, the review’s finding that only 57% of patients with a positive drug screen in one cohort had disclosed recreational drug use has real policy relevance: stigma and legal concern may still suppress honest disclosure even where cannabis use is legal, which can delay recognition of a genuine cardiovascular trigger.
The review supports selective toxicology screening in younger ACS patients with few traditional risk factors as a diagnostic aid, not a punitive tool, and its authors caution that routine indiscriminate screening can raise legitimate concerns about cost, stigma, confidentiality, and employment consequences that policy and clinical practice should take seriously.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What did this review actually study?
It is a narrative literature review synthesizing evidence from PubMed/MEDLINE and Scopus, searched through June 2026, on how recreational drugs, including cannabis, cocaine, amphetamines, MDMA, opioids, LSD, and synthetic cannabinoids, may trigger acute coronary syndrome. It is not a systematic review or meta-analysis.
Does this review show that cannabis causes heart attacks?
It cites evidence that cannabis use is associated with an increased short-term risk of myocardial infarction, particularly within the first hour after use, and proposes several biological mechanisms. It does not establish a proven, dose-response causal relationship in humans, and its own authors say some of the underlying mechanisms need further validation.
How common is cannabis in patients with acute coronary syndrome, according to this review?
In a multicenter ADDICT-ICCU study cited in the review, cannabis was the most frequently detected recreational drug among intensive cardiac care unit patients, found in 9.1% of patients, ahead of opioids (2.1%), cocaine (1.7%), and amphetamines (0.7%).
How does cannabis compare with cocaine in this review?
Cocaine remains the best-studied recreational drug for ACS in this literature, with more extensive mechanistic and quantitative data, including a roughly 24-fold increase in MI risk in the first hour after use in a cited case-crossover study. Cannabis is associated with a smaller, nearly fivefold first-hour risk increase in the review’s cited data, and its mechanistic evidence base is comparatively less developed.
What mechanisms does the review propose for cannabis-associated heart attacks?
The review proposes THC-driven sympathetic activation and norepinephrine release, coronary vasospasm, carboxyhemoglobin elevation from smoking, oxidative stress and endothelial dysfunction, and possible THC-related platelet activation and procoagulant effects, based on a mix of case reports, in vitro studies, and mechanistic research.
Is a positive cannabis toxicology screen proof that cannabis caused a patient’s heart attack?
No. The review notes that cannabinoids can remain detectable in urine for a long time, especially after frequent or chronic use, so a positive screen confirms past exposure but does not by itself establish that cannabis use was recent enough to have triggered the acute cardiac event.
Should beta-blockers be avoided in cannabis-associated ACS the way they sometimes are in cocaine-associated ACS?
Not automatically. The review states that in cannabis-associated ACS, beta-blocker therapy should be individualized according to hemodynamic status, left ventricular function, conduction abnormalities, and the underlying mechanism of ischemia, rather than withheld or given by default.
Does using cannabis alongside other substances increase cardiovascular risk further?
The review cites evidence that combining cocaine and cannabis appears to increase cardiovascular risk beyond either drug alone, and notes that polysubstance detection generally was associated with higher odds of in-hospital major adverse cardiac events than single-drug detection in the ADDICT-ICCU cohort.
Is this a peer-reviewed source?
Yes. It is a peer-reviewed narrative review published in Medicina (Kaunas, Lithuania), an open-access, PubMed-indexed journal, online July 30, 2026 (PMID 42654374, DOI 10.3390/medicina62081477).
What are the main limitations of this review’s cannabis-specific evidence?
It is a narrative, not systematic, review with no formal risk-of-bias assessment or pooled effect sizes. Much of the cannabis-specific mechanistic evidence comes from case reports and in vitro studies, and the authors themselves state that the human validation of proposed cannabis mechanisms remains incomplete, while the relationship between marijuana use and post-MI mortality is described as controversial given limitations in the underlying cohort data.
